Cannabis stocks were mostly higher on Monday, after the U.S. Food and Drug Administration said it is expediting its effort to create a regulatory framework for CBD with plans to publish a report on its progress by early fall.
1/3 FDA is expediting its work to address the many questions about cannabidiol . This is an important national issue with public health impact, & an important topic for American hemp farmers and many other stakeholders. pic.twitter.com/XQbXb0KspU Organigram Chief Executive said on the earnings call that the increased costs were due to an ultimately unsuccessful experiment it conducted with how it planted new harvests.
The company’s Danish partner, Stenocare A/S STENO, +2.53% said it received and sold some of the illegal pot. Exporting unlicensed cannabis is an indictable offense, according to Canadian laws.
Interesting to watch. How much of this is a hype? Is everything already priced in and the current rally is purely based on the future/speculation?
대한민국 최근 뉴스, 대한민국 헤드 라인
Similar News:다른 뉴스 소스에서 수집한 이와 유사한 뉴스 기사를 읽을 수도 있습니다.
출처: BusinessInsider - 🏆 729. / 51 더 많은 것을 읽으십시오 »